Ticker

Sol-Gel Technologies (NASDAQ: SLGL - Get Free Report) and Assembly Biosciences (NASDAQ: ASMB - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership. Valuation and Earnings This table compares Sol-Gel

Sol-Gel Technologies Ltd. (NASDAQ: SLGL - Get Free Report) major shareholder Opaleye Management Inc. acquired 22,497 shares of the stock in a transaction on Wednesday, December 31st. The stock was bought at an average price of $41.99 per share, for a total transaction of $944,649.03. Following the transaction, the insider owned 443,739 shares in the company,

Sol-Gel Technologies Ltd. (NASDAQ: SLGL - Get Free Report) major shareholder Opaleye Management Inc. acquired 8,638 shares of Sol-Gel Technologies stock in a transaction dated Monday, December 29th. The shares were bought at an average cost of $41.85 per share, with a total value of $361,500.30. Following the transaction, the insider owned 386,073 shares in the

Sol-Gel Technologies Ltd. (NASDAQ: SLGL - Get Free Report) major shareholder Opaleye Management Inc. acquired 35,169 shares of Sol-Gel Technologies stock in a transaction that occurred on Tuesday, December 30th. The stock was acquired at an average price of $41.99 per share, with a total value of $1,476,746.31. Following the completion of the purchase, the insider

Sol-Gel Technologies ends development of SGT-210 in Darier disease after Phase 1b data show no efficacy versus vehicle.